Ionis Pharmaceuticals, Inc. (IONS) Stock
Fundamentals
Source: third-party data provider, as of October 12, 2026
Compare with IONS
Recent news
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
IONS
Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs
Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs
IONS
Ionis announces positive interim data from partner Roche's Phase 3 IMAgINATION study in IgA nephropathy (IgAN)
Ionis announces positive interim data from partner Roche's Phase 3 IMAgINATION study in IgA nephropathy (IgAN)
IONS
Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study
IONSNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 40.57
- MACD 12/26/9
- -2.80
- EMA 9 of MACD
- -3.24
- MACD histogram
- 0.44
- SMA 50
- $52.81
- Price below SMA 50
- EMA 50
- $52.03
- Price below EMA 50
- SMA 200
- $69.52
- Price below SMA 200
- EMA 200
- $66.13
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 9, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 13 analysts
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.78 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
IONSIonis Delivers Positive Late-Stage Results for Two Partnered Drugs
Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs
IONSIonis announces positive interim data from partner Roche's Phase 3 IMAgINATION study in IgA nephropathy (IgAN)
Ionis announces positive interim data from partner Roche's Phase 3 IMAgINATION study in IgA nephropathy (IgAN)
IONSOtsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study
IONS
Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment
Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment
IONS
Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS
Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS
IONS
Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook
Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook
IONS
Ionis Pharmaceuticals Eyes TRYNGOLZA Growth as Pipeline Faces Cardio Setbacks
Ionis Pharmaceuticals Eyes TRYNGOLZA Growth as Pipeline Faces Cardio Setbacks
IONS
Cathie Wood Is Loading Up on Ionis Pharmaceuticals (IONS) Stock. Here's the Bet She's Making.
Cathie Wood Is Loading Up on Ionis Pharmaceuticals (IONS) Stock. Here's the Bet She's Making.
IONS
Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall
Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall
IONSNews tone: automated (AI) classification of the article's content, not a price prediction.
About Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Brett P. Monia Ph.D. | Founder, CEO & Director | 1961 |
| Ms. Elizabeth L. Hougen M.A., M.B.A., M.S. | Executive VP of Finance & CFO | 1962 |
| Mr. Patrick R. O'Neil Esq. | Executive VP, Chief Legal Officer, General Counsel & Corporate Secretary | 1974 |
| Dr. Eric E. Swayze Ph.D. | Executive Vice President & Head of Research | 1966 |
| Mr. Brian Birchler | Executive Vice President of Corporate & Development Operations | 1966 |
| Dr. Richard S. Geary Ph.D. | Strategic Consultant | 1958 |
| Dr. Eugene Schneider M.D. | Executive VP, Chief Clinical Development & Operations Officer | 1973 |
| Mr. Darren Gonzales | Chief Accounting Officer & Senior VP | — |
| Dr. C. Frank Bennett BSc, Ph.D. | Executive VP & Chief Scientific Officer | 1957 |
| Mr. D. Wade Walke Ph.D. | Senior Vice President of Investor Relations | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 12, 2026
Technical indicators
- RSI 14
- 40.57
- MACD 12/26/9
- -2.80
- EMA 9 of MACD
- -3.24
- MACD histogram
- 0.44
- SMA 50
- $52.81
- Price below SMA 50
- EMA 50
- $52.03
- Price below EMA 50
- SMA 200
- $69.52
- Price below SMA 200
- EMA 200
- $66.13
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 9, 2026. Technical data, not a recommendation.
Analyst views
13 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $54.00
- Average
- $82.42
- High
- $104.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -5.0 | -19.7 | +18.8 | |||||||||
| 2022 | -2.5 | +5.9 | +8.7 | -5.5 | -4.8 | +3.1 | -1.3 | +13.4 | +1.8 | -1.8 | -9.0 | -6.0 |
| 2023 | +6.1 | -10.3 | -0.6 | +0.1 | +14.6 | -4.4 | +0.9 | -2.3 | +12.0 | +1.9 | +9.3 | -2.0 |
| 2024 | -2.8 | -11.3 | -4.6 | -6.1 | -12.6 | +22.9 | +5.0 | -7.1 | -15.3 | -1.7 | -7.8 | -3.2 |
| 2025 | -8.0 | +3.3 | -7.5 | +12.7 | +5.7 | +15.8 | +7.6 | -0.9 | +13.8 | +12.9 | +12.3 | -3.5 |
| 2026 | +3.8 | -2.3 | -8.4 | -0.5 | +1.6 | +5.2 | -34.6 | +10.8 | -25.4 | +2.9 |
